Navigation Links
Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
Date:3/4/2009

mpany's ability to achieve its business goals, the effect of the Company's decision to focus primarily on the application of PCT-enhanced protein digestion for the mass spectrometry market and the advantages of PCT in this market, and the use of PCT in biomarker discovery, soil and plant biology, counter-bioterror, and tissue pathology applications. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT System; changes in customer's needs and technological innovations; the Company's sales force may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods, particularly in the mass spectrometry market; scientists may not be able to duplicate the results achieved at particular laboratories having already used PCT; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company will need additional capital sooner than the second quarter of 2010. Further, the Company expects that it will need additional capital to fund its continuing operations beyond the second quarter of 2010. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation
'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
2. Pressure BioSciences, Inc. Issued First Patent in Canada
3. Interventional Cardiologists Nico Pijls, Bernard De Bruyne to Discuss Benefits of Measuring Coronary Pressure in Improving Multivessel PCI at ESC Congress 2007
4. Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320
5. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
6. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
7. Pressure BioSciences, Inc. Provides Corporate Update
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. The sensitive side of carbon nanotubes: Creating powerful pressure sensors
10. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
11. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), the leading ... methodologies relating to cannabis, today announced that it has ... from an existing stockholder of the Company. , ... from one of our existing stockholders,” stated Mark ... help accelerate our planned expansions into the Connecticut and ...
(Date:11/22/2014)... 2014 The “Chiral Chromatography Columns ... Material (Metal, Glass, Plastic), by Application [GC, LC ... Forecast to 2018” analyses and studies the major ... America, Europe, Asia, and Rest of the World. ... figures spread through 135 pages and in-depth TOC ...
(Date:11/22/2014)... 21, 2014   ... Commercial Officer zu KLOX    ... Chief Financial Officer bestellt    KLOX ... seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    ... "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... The science of light and how it ... than 200 primary students in a traveling program organized ... Otago Physics Department and funded by an SPIE ... the university’s OSA/SPIE Student Chapter visited six primary schools ... from small, rural schools hands-on lessons in optics and ...
Breaking Biology Technology:CannLabs Secures $750,000 Line Of Credit 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3
... , MALVERN, Pa. and WALTHAM, Mass., Nov. ... find that the leading driver of antibiotic selection in ... and gram-negative pathogens. Due to the variety of organisms ... that they look primarily for agents that provide appropriate ...
... , MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. ... a randomized Phase 2B study of AEG35156, a targeted ... , The study, entitled "An Open-Label Randomized Phase 2 ... AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin ...
... ... Consortium (IGSC) to Coordinate Best Practices in Risk Reduction ,Five Member Companies Represent ... ... leading gene synthesis companies today announced agreement that they will apply a common screening ...
Cached Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
(Date:11/3/2014)... study published in this month,s Proceedings ... activity of a recently discovered communication molecule of the ... been known to limit inflammation and the current study ... inhibits the ability of the immune system to recognize ... underlies IL-37,s effect on the immune system now allows ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... reprogrammed stem cells from a key organ in the immune ... regeneration. Their research shows that it is possible to ... genetic modification. Researchers, who used rat models, grew ... our immune systems in the laboratory using conditions for ...
... destroys brain cells and their connections (called synapses), causing ... hobbies and daily life. Symptoms can be alleviated, in ... States as Namenda), which is currently FDA-approved to treat ... Stuart A. Lipton, M.D., Ph.D., Director of the Del ...
... Tech College of Engineering researchers have received a $60,000 ... occurring microbes can best be used to eat away ... Their choice of weapon: Geometry. Fueled by oxygen, ... of crude oil without the use of additional chemicals. ...
Cached Biology News:Stem cell versatility could help tissue regeneration 2Study explains why Alzheimer's drug is both safe and effective 2Does the shape of crude oil remnants impact rate of biodegradation? 2Does the shape of crude oil remnants impact rate of biodegradation? 3
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
HSV-1 gE Envelope Protein (9H3)...
... functionally defined by their capacity to self ... multiple specialized progenitor cells, which can commit ... stem cells (NSCs) are capable of differentiating ... and oligodendrocytes. During the isolation and expansion ...
Lineage cocktail 1 (lin 1) 50 tests...
Biology Products: